

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/25/2015; Page 1

Suggested Formula	Methylprednisolone 4 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 157

# **SUGGESTED FORMULATION**

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Methylprednisolone Acetate, USP*	0.089	g				
Chocolate Flavor	0.1	mL				
Glycerin, USP	1.0	mL				
Medisca Oral Mix (Flavored Suspending Vehicle)	50.0	mL				
Medisca Oral Mix (Flavored Suspending Vehicle)	q.s. to 100.0	mL	(8)	)		

<sup>\*</sup>Note: Methylprednisolone Acetate 0.089 g is equivalent to Methylprednisolone 0.080 g.

# **SPECIAL PREPARATORY CONSIDERATIONS**

Ingredient-Specific Information		5, >
<b>Light sensitive</b> (protect from ligh	t whenever possible): Meta	hylprednisolone Acetate
Hygroscopic (protect from moist	ure whenever possible): Glyo	cerin
Suggested Preparatory Guidelines		
Non-Sterile Preparat	ion Sterile Preparation	
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error commeasure an additional 5 to 9% of the	nsiderations during preparation, it is suggested to e required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coat should always be worn.	, disposable gloves, eyewear and face-masks
	•	ry small quantities of ingredients. All calculations verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/25/2015; Page 2

Suggested Formula	Methylprednisolone 4 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 157
----------------------	---	-----	-----------

# **SUGGESTED PREPARATION (for 100 mL)**

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Methylprednisolone Acetate, USP §	0.089	g			
Chocolate Flavor	0.1	mL			
Glycerin, USP §	1.0	mL			
Medisca Oral Mix (Flavored Suspending Vehicle)	50.0	mL	<b>⊗</b>		
Medisca Oral Mix (Flavored Suspending Vehicle)	q.s. to 100.0	mL	, X.C.		

\* Takes into account increased batch size conversions and density conversions, if required.

End result: Homogeneous liquid-like dispersion.

§ Weigh / measure just prior to use.

	Preparatory Instruction
1.	Powder-liquid preparation:
	A. Levigate the Methylprednisolone Acetate with the Glycerin.
	End result: Homogeneous liquid-like dispersion.
2.	Medium incorporation:
	A. In the given order, sequentially add the following ingredients to the Oral Mix (Flavored Suspending Vehicle) (50.0 mL <i>plus</i> processing error adjustments):
	-Homogeneous liquid-like dispersion (Step 1A) -Chocolate Flavor
	Specifications: Continuously mix, using high-shear mixing techniques.
	End result: Homogeneous liquid-like dispersion.
	Note: Add the next ingredient, once the previous one has been completely added and dispersed.
3.	Filling to volume:
	A. Add additional Oral Mix (Flavored Suspending Vehicle) to the mixture (Step 2A) to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).
	Specifications: Continuously mix, using high-shear mixing techniques.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/25/2015; Page 3

Suggested Formula	Methylprednisolone 4 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 157
1 ommun			

# 4. **Product transfer:**

A. Transfer the final product into the specified dispensing container (see "Packaging requirements").

<u>Note</u>: Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.

### **SUGGESTED PRESENTATION**

Estimated Beyond-Use Date		14 days, refrigerated, as per USP.	Packa Requirem		<ul> <li>Tightly closed, light-resistant dispensing bottle.</li> <li>To be dispensed with a metered-dose measuring device.</li> </ul>		
	1	Use as directed. Do not exceed dose.	l prescribed	6	May produce psychological and/or physical dependence.		
Auxiliary Labels	2	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.			Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.		
	3	Shake well before use.			Cap tightly after use.		
	4	Protect from light.		9	Keep out of reach of children.		
	5	Keep refrigerated. Do not freeze	).				
Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as			nsing container as deemed necessary.				
Patient Instructions Contact your pharmacist in the event of adverse reactions.				ns.			

### **REFERENCES**

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition</i> . American Pharmaceutical Association; 2012: 239.
2.	Depo-Medrol. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2014: 830.
3.	Glycerin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 7 <sup>th</sup> <i>Edition</i> . American Pharmaceutical Association; 2012: 324.
4.	Methylprednisolone Acetate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition.</i> London, England: The Pharmaceutical Press; 2009: 1530.
5.	Methylprednisolone (Monograph). In: O'Neil MJ. <i>The Merck Index 15<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #6184.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

4/25/2015; Page 4

	uggested Formula	Methylprednisolone 4 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 157				
6.	6. Methylprednisolone Acetate. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 5<sup>th</sup> Edition.</i> American Pharmaceutical Association; 2012: 321.							
7.	7. Methylprednisolone Acetate (Monograph). <i>United States Pharmacopeia XXXVII / National Formulary 32</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2014: 3795.							
8.	Methylprednisolone. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26<sup>th</sup> Edition.</i> Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 1025.							
9.	USP <795>. <i>United States Pharmacopeia XXXVII / National Formulary 32</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2014: 403.							
				•				

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.